EUPRAXIA PHARMACEUTICALS INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $46.92 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-03-13
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|
| 2025-12-31 | $46.92M 40-F · filed 2026-03-13 |
| 2024-12-31 | $15.71M 40-F · filed 2026-03-13 |
| 2023-12-31 | $256.97K 40-F · filed 2025-03-20 |
| 2022-12-31 | $6.24M 40-F · filed 2024-04-01 |